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Infections in Kidney, Heart, and Liver Transplant 
Recipients on Cyclosporine 
D~ -
M. Ho, C. P. Wajszczuk, A. Hardy, J. S. Dummer, T. E. Starzl, T. R. Hakala, and H. T. Bahnson 
OUR study involves 216 patients trans-planted at the University of Pittsburgh 
from 1978 to 1983 (Table I). This includes 64 
kidney patients on cyclosporine (CsA), of 
which 21 were in a randomized trial of CsA, 
with 17 patients on azathioprine (AZA).I 
Since the latter was a small number, 59 renal 
patients on AZA from 1978 to 1980 are 
included for comparison. Except for the 
immunosuppressive drugs, all renal transplant 
recipients received comparable management 
largely from the same surgical team. In addi-
tion, from 1981 to 1983, we followed 33 heart 
and 43 liver transplant recipients who were all 
on CsA. This drug was first introduced in 
Pittsburgh in March 1981. A preliminary 
report of infections in these groups has been 
published. 2 This article provided additional 
patients, data, and follow-up material. 
MATERIALS AND METHODS 
All renal groups were followed for at least 6 months. 
Heart and liver patients were followed for a minimum of 3 
months. The mean duration of follow-up for the latter 2 
groups were 277 and 221 days, with a range of 90-400 
and 90-594 days. Most patients received intravenous 
methylprednisolone I day prior to surgery. CsA was given 
according to Starzl et al. l On the day of surgery, 17.5 
mg/kg/day was given orally, and attempts were made to 
reduce the dose to 3-10 mg/kg/day, Patients on AZA 
were begun on 5 mg/kg/day, with maintenance of 2.5 
mg/kg/day. All patients on CsA and AZA also received 
prednisone. Patients on CsA received somewhat less 
cumulative prednisone than those on AZA.' The 3 types 
of transplant patients on CsA were on similar regimens, 
except 6 of 33 cardiac recipients also received antithymo-
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cyle globulin for rejection. They were not significantly 
different in terms of episodes of infection. 'l>' 
Infections are defined as clinically significant disease 
based on clinical and laboratory diagnosis, except in the 
case of virus infections, where the distinction between 
infection and symptomatic infection or disease is made. .... 
Throat washings, urine samples, and blood buffy coats 
were obtained routinely for cytomegalovirus (CMV) and 
herpes simplex virus (HSV) cultures weekly for the first 8 
postoperative weeks, biweekly during the third month, 
and monthly thereafter. Serum samples were obtained, ~ 
when possible, from recipients and donors prior to trans-
plantation and from recipients at monthly intervals after 
transplantation. CMV and Epstein-Barr virus CEBV) 
serology were performed as previously described." ...... 
RESULTS 
Table 2 is a summary of infections in all the 
1981-1983 groups. Consider first the renal <{/1 
groups. The percent of patients who had at . 
least one infection, as well as mean episodes of 
infection per patient, was significantly higher 'Q 
in the randomized azathioprine group (88% ~ 
and 2.18) than in the CsA group (61 % and 
0.98). None of the infections in the renal 
groups was associated with deaths, of which ~g~_ 
there was only one. 
The cardiac and liver transplant groups on 
CsA had more infection than the renal group _.,,_ 
on esA immunosuppression. The sites ot 
infections in the kidney, heart, and liver 
groups varied (Table 3). Most frequent infec-
tions for the 3 groups, respectively, were uri -
nary tract, pulmonary and intrathoracic, and 
abdominal and gastrointestinal infections. 
Kidney recipients had the lowest frequency of "!l" -
bacteremias. Only the liver group had fUL 
gemia. Perhaps more important is the fact 
that mortality associated with severe infec- : 
tions was significant in the heart and live ... ~ 
groups. Many of the liver group died acutel~ 
with many infections. This is reflected in tt 
fact that 50% of all episodes of infection W'2 .' 
acquired I month after liver transplantatiOl 
To reach the same proportion, cardiac '-
patients took 3 months, 
, .: 
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INFECTIONS IN TRANSPLANT RECIPIENTS ON CSA 
Table 1. Transplant Groups at PUH" FOllowed for Infections 
Time of Type No. of 
Transplant Transplant Patients 
1981-1982 Kidneyt 64 
1981-1982 Kidneyt 21 
1981-1982 Kidneyt 17 
1978-1980 Kidney 59 
1981-1983 Heart 33 
1981-1983 Liver 43 
"Presbyterian-University Hospital, University of Pittsburgh. 
t All kidney patients on CsA. 
tPatients on randomized GsA, AZA trial. 
Mean 
Age Immunosuppression 
36 CsA 
41 CsA 
41 AZA 
33 AZA 
40 CsA 
36 CsA 
Table 2. Infections and Fatalities in 1981-1983 Transplant Recipients 
Renal Transplant Groups 
Random Random AIICsA Cardiac 
AZA CsA Renal Transpl. 
Patient Characteristic In - 17) In- 21) In - 64) In - 33) 
All infections 
Percent Infected" 88% 71% 61% 76% 
Total episodes 37 24 63 52 
Mean episodest 2.18 1.14 0.98 1.58 
Nonviral infections 
Percent infected 82% 43% 41% 58% 
Total episodes 28 13 39 30 
Mean episodes 1.65 0.62 0.61 0.91 
Infection-associated 
deaths/total deaths 0/0 0/0 0/1 9/14 
"Percent patients developing one or more infections. 
tTotal number of episodes divided by number of patients. 
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Duration of 
Follow-up 
6 months- 1 year 
6 months- 1 year 
6 months-1 year 
6 months- 1 year 
3 months-1 year 
4 months- 1 year 
Liver 
Transpl. 
In-43) 
81% 
98 
2.23 
65% 
70 
1.63 
17/20 
Table 3. Site of Infections According to Type of Transplant Patient on Cyclosporine 
Type of 
Transplant 
Kidney 
Heart 
Liver 
Frequent Sites of Infection 
Percent of 
Site All Infections 
Urinary tract 41% 
Pulmonary and 38% 
intrathoracic 
Abdominal and 35% 
gastrointestinal 
Bacterenlias Fungemia 
5% 0% 
24% 0% 
30% 16% 
Table 4. Organisms Causing Infections in 1981-1983 Transplant Recipients 
Renal Transplant Groups 
Random Random AIICsA Cardiac 
AZA CsA Renal Transpl. 
Organism In - 17) In - 211 (n- 64) In - 33) 
Gram-negative 
aerobes 18 (53)" 10 (39) 37 (34) 13 (33) 
All gram-positive 11 (53) 7 (29) 13 (17) 10(24) 
Staphylococcus 7 (41) 1 (5) 4(6) 4 (12) 
Fungus 0(0) 1 (5) 1 (2) 1 (3) 
Other 12 (71) 13 (48) 30 (36) 27 (58) 
Total 46 (88%) 13 (86%) 81 (67%) 51 (79%) 
"N umber of isolates (parcent patients infected by isolate). 
Infection-
Associated 
Deaths 
0% 
27% 
40% 
Liver 
Transpl. 
(n- 43) 
36 (49) 
29 (58) 
12 (23) 
22 (44) 
23 (47) 
110 (88%) 
----
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Table 5. Effect of Azathioprine and Cyclosporine on Infections in Renal Transplant Recipients 
Group 
Random AZA 
1978-1980 AZA 
CsA 
Bacteremias 
5/17 (29%) 
11/59(19%) 
3/64 (5%) 
Staph 
BacteremIa 
2/17 (12%) 
5/59 (9%) 
0/64 (0%) 
'Based on data for all renal transplantation 1978-1982. 
Table 4 presents organisms responsible for 
in fections in the 1981-1983 transplant 
groups. The following are notable. (1) Gram-
iicg<itive aer~bes were significant pathogens in 
aJl groups. (2) Gram-positive infections, par-
ti,;ularly staphylococcal infections, were more 
common in the randomized AZA group than 
all other groups on CsA. (3) Severe fungus 
infections were a serious problem only in the 
liver transplant patients. Forty-four percent of 
liver patients had serious fungal infections 
and 16% were fungemic. The most common 
agent was Candida, which caused serious 
infections in 15 patients. Of these, 3 had 
disseminated disease, 6 had fungemia, 7 had 
abdominal, and 3 had lung and chest infec-
tions. Four patients had aspergillosis, in whom 
one produced dissemination and 3 produced 
pneumonia or chest infections. There was one 
severe Mucor wound infection and one crypto-
~DFccal meningitis. (4) Symptomatic viral 
nfections, included here under "other," were 
a problem in cardiac transplant patients and 
are discussed below. 
Renal patients on AZA had more infections 
that were more severe and were predomi-
nately Staphylococcal (Table 5). This state-
ment is substantiated by including data from 
Lung Lung 
Infection Staph Pneumocysti<:< 
5/17 (29%) 3/17 (18%) 
23/59 (39%) 5/59 (8%) 6/179 (3%)' 
5/64 (8%) 0/64 (0%) 14/156 (::%)+ 
the 1978-1980 AZA group, whose incidence 
of infection was similar to the small randolll-
ized AZA group of 1981-1983.2 The two 
AZA groups had 29% and 39% pneumonias, 
as opposed to 8% for the CsA group. Stap'lylo-
coccal penumonias and bacteremias were ak:l 
more common in patients on AZA. In con-
trast, the incidence of non-life-threatening 
urinary tract infections were almost identical: 
41%, 39%, and 42% (not shown in tab;e). 
Pneumocystis pneumonia, however, may be a 
special problem in renal patients on CsA. Our 
total Pittsburgh incidence rates for the AZA 
and CsA groups prior to the institution 
trimethoprim-sulfa prophylaxis in September 
1982 were 3.4% and 9.0%, respectively, which 
are significantly different. This problem is 
discussed by Hardy et al. elsewhere in this 
issue. 
Virus infections, particularly of the herpes-
virus group (CMV, HSV, VZV, and EBV' 
are frequent occurrences after organ trans-
plantation.5 In previous experience, the degree-
and type of immunosuppression has been crit; 
cal in determining the morbidity. In renal 
transplant recipients, antithymocyte globulin 
has been associated with more symptomatic 
infection. 6 Primary infections, i.e., those 
Table 6. Herpesvirus Infections in 1981-1983 Transplant Recipients 
Renal Transplant Groups 
Random Random 
AZA CsA 
In - 17) In - 20) 
Sympto- Sympto-
Virus No. (%) matlC No. 1%) matte No. 
AIICMV 13 (761 15 (75) 46 
CMV VIremia 5 (26) 1 8 (40) 1 20 
Herpes simplex 9 (53) 6 8 (40) 6 26 
Herpes zoster 0 10) 0 (5) 2 
Total symptomatic 7141 )t 7(35) 
'Signlficantly different from other CsA groups (X' test!. p < 0.05. 
tNumb-:;r nRtients symptomatic (% of group). 
AllCsA Cardiac Liver 
Renal Transpl. Transpl. 
In - 60) In - 29) In ~ 271 
Sympto- Sympto- Sympto-
1%) matic No. 1%) matlc No 1%1 matlc 
(77) 5 27 (93) 10· 21 157) 12 
(33) 5 18 (621 ~l" 15 1411 Ie 
(43) 14 16 (55) 8 19 (51) 9 
(3) 2 3 !10) 3 2 i5) 2 
19132) 17(59). 1814;::) 
.), 1983 
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Table 7. Primary and Reactivation CMV Infections in 1981 -1983 Transplant Recipients 
Renal Transplant Groups 
Random Random 
AZA CsA 
Pretransplant In - 171 In ~ 201 Serologic 
Statal:> (iT 1%1- Syt liT 1%1 Sy 
Posilive 10/13 (77) 1 15/17 (88) 
Neyative 3/4 (75) 0 0/3 (0) 
Totallnfected 13/17 (76) 15/20 (75) 
-I/T (%). infected/total evaluable (%). 
rSy. symptomatic patients. 
occurring in seronegative recipients, have 
been iound to be more symptomatic.7 
Hvrpesvirus infections in our transplant 
groups are presented in Table 6. The first row 
describes all CMV infections diagnosed by 
isol2 ting the virus from routine throat, urine, 
or bood buffy coat specimens. The majority 
of p2tients became infected, and the rates are 
ndistinguishable from results from previous 
c:'e:; of patients, most of whom were on 
A£:A. As a group of agents, herpesviruses and 
gram-negative aerobes are the most frequent 
causes of symptomatic infections. 
, The incidence of CMV viremia varied from 
21'-% to 62%. All patients who had symptom-
atic CMV infection were viremic, but there 
,./ere also many viremic patients who were not 
symptomatic. The percent of patients with 
symptomatic disease due to CMV and herpes-
,-uses in general was significantly higher in 
K::~ cardiac group. They also had more 
viremia due to CMV. 
Of the patients with symptomatic CMV 
., ,xtion, there were three cases of CMV 
::umonitis in the renal group on CsA. In a 
'parate communication (Hardy et aI., this 
.ue), the relationships of CMV infection to 
1'reumocystis pneumonia is discussed. Five of 
AIICsA Cardiac Liver 
Renal Transpl. Transpl. 
In ~ 601 In - 251 In - 181 
liT 1%1 Sy liT 1%1 Sy lIT 1%1 Sy 
42/51 (82) 4 15/15 (100) 5 7/10 (70) 2 
4/9 (44) 9/10 (90) 5 5/8 (62) 2 
46/60 (77) 5 24/25 (96) 10 12/18 (66) 4 
the ten symptomatic cases in the cardiac 
group were associated with CMV in the lung. 
One was found in association with pneumo-
cystis in a lung biopsy and four were found at 
autopsy. There were 12 symptomatic cases in 
the liver group, including one case of intersti-
tial pneumonia and three instances of dissemi-
,nated disease found at autopsy. 
Primary and reactivation CMV infections 
are listed in Table 7. Except for a suggestion 
in the case of cardiac transplant recipients 
that primary infection in previously seronega-
tive subjects resulted in more symptomatic 
infection than reactivation infection, the num-
bers are too small to incriminate primary 
more than reactivation infections in symptom-
atic disease. 
Rates for EBV infection are shown in Table 
8. Cardiac transplant recipients had more 
infection, and only they had probable symp-
tomatic disease due to EBV (see Dummer et 
aI., this issue). However, our total experience 
is stilI rela tivel y small. 
SUMMARY AND CONCLUSIONS 
Renal patients on CsA had fewer bactere-
mias, pneumonias, and gram-positive staphy-
lococcal infections than renal patients on 
Table 8. Epstein-Barr Virus Infections in 19B1-1983 Transplant Recipients 
Renal Transplant Groups 
Pretransplant Random Random AIICsA Cardiac Liver 
IgG-VCA AZA esA Renal TranspL TranspL 
Negative 0/0 0/1 1/3 3/3 0/1 
Positive 2/17 3/19 5/34 8/21 1/13 
Total infected 2/17 3/20 6/37 11/24· 1/14 
Percent 12% 15% 16% 46% 7% 
i 'Significantly different from all other groups on CsA, p < 0.01 . F've were symptomatic; two had primary infections. onf : lad 
BV lymphoma. 
f 
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AZA. Patients on CsA may be at risk for 
pneumocystis. 
Severity and site of infection is largely 
determined by type of transplantation. Heart 
and liver transplant recipients had serious 
chest and abdominal infections. 
Serious fungal infections occurred largely 
in liver transplant recipients. 
HO ET Al. 
Almost every patient was infected with 
CMV; 8%-34% developed symptomatic dis-
ease. This was always associated with vire- ~ 
mla. 
Heart transplant recipients developed more 
CMV viremia and more EBV infection. They 
also had more symptomatic disease from all ... 
herpesviruses. 
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